抗マラリア薬設計の新たな経路を特定(Researchers identify potential new route for antimalarial drug design)

ad

2026-05-06 バース大学

University of Bathの研究チームは、マラリア原虫に対する新たな抗マラリア薬開発経路を発見した。研究では、原虫が生存や増殖に必要とする特定の生化学的経路や酵素機能を詳細に解析し、既存薬とは異なる作用点を標的にできる可能性を示した。現在、マラリア治療では薬剤耐性の拡大が深刻化しており、新規作用機序を持つ薬剤開発が急務となっている。研究者らは、今回特定した分子機構を阻害することで、原虫の代謝や細胞機能を効果的に停止できる可能性があると報告した。また、この標的はヒト細胞への影響が比較的小さいと考えられ、副作用を抑えた治療薬設計にもつながる可能性がある。今後は候補化合物の最適化や前臨床試験を進め、薬剤耐性マラリアにも有効な次世代治療薬の実用化を目指す。研究成果は、世界的な感染症対策や熱帯病制御への貢献が期待されている。

<関連情報>

ヒドロキサム酸系阻害剤は、マラリア原虫アミノペプチダーゼPに対する選択性の構造的決定因子を明らかにする Hydroxamate-based inhibitors reveal structural determinants of selectivity for Plasmodium falciparum aminopeptidase P

Belinda J. Mills ∙ Kyle S. Gregory ∙ Gyles E. Cozier ∙ … ∙ R. Elwyn Isaac ∙ Richard Foster ∙ K. Ravi Acharya
Journal of Biological Chemistry  Published:March 16, 2026
DOI:https://doi.org/10.1016/j.jbc.2026.111372

抗マラリア薬設計の新たな経路を特定(Researchers identify potential new route for antimalarial drug design)

Abstract

The malarial parasite, Plasmodium falciparum (Pf), utilizes aminopeptidases in the breakdown of hemoglobin-derived oligopeptides to release amino acids for protein synthesis during growth and asexual reproduction of erythrocytic stages of the parasite. However, a N-terminal peptide bond that involves proline is difficult to hydrolyze. Aminopeptidase P (APP) is capable of cleaving peptide bonds with proline in the second position. Inhibition of PfAPP is therefore an attractive strategy for developing therapeutics for the treatment of malaria by limiting the supply of amino acids at the erythrocytic stage. We employed the structure-activity relationship of an existing APP inhibitor, apstatin, to design a more potent PfAPP inhibitor by introducing a hydroxamic acid metal-binding group in place of the amino-alcohol of apstatin and an aromatic P4′ moiety. A hydroxamic tetrapeptide with phenylalanine at P4′ (6d) greatly increased the inhibitory potency (apstatin Ki, 16 μM; 6d, Ki 685 nM). Replacing the P3′ proline of 6d with a 2-substituted piperidine (6e) further improved the potency (Ki, 24 nM). Crystal structure analysis of PfAPP in complex with 6d and 6e showed binding at the active site with coordination of the hydroxamic acid metal binding group to the di-metal center, and several protein–inhibitor interactions involving domains II and III. A comparison of PfAPP-6e with human APP1 indicated that the P4′ phenylalanine drives inhibitor potency and selectivity toward PfAPP, by forming an interaction with Tyr617 of the adjacent monomer within the dimer. The details presented here should be useful for the future design of potent and selective PfAPP inhibitors.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました